The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of SBP-101, in combination with gemcitabine and nab-paclitaxel, in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
 
Dusan Kotasek
No Relationships to Disclose
 
Adnan Nagrial
Honoraria - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Boehringer Ingelheim; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; MSD; MSD; MSD; MSD; Roche; Roche; Roche; Roche
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
 
Sumit Lumba
No Relationships to Disclose
 
Niall C. Tebbutt
Honoraria - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Roche; Roche; Roche; Roche
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Merck Sharp & Dohme; Roche; Roche; Roche; Roche
Research Funding - Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Roche; Roche; Roche; Roche
 
Thomas J. George
Consulting or Advisory Role - Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Bayer/Onyx; Merck; Merck; Merck; Merck
Research Funding - AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bayer/Onyx (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Pharmacyclics (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Seagen (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst); Tesaro (Inst)
 
Sheri Lynn Smith
Stock and Other Ownership Interests - 3M; 3M; 3M; 3M; Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma
Consulting or Advisory Role - Celcuity; Celcuity; Celcuity; Celcuity; Clinigen Group (Inst); Clinigen Group (Inst); Clinigen Group (Inst); Clinigen Group (Inst); Humanetics (Inst); Humanetics (Inst); Humanetics (Inst); Humanetics (Inst); IGF Oncology (Inst); IGF Oncology (Inst); IGF Oncology (Inst); IGF Oncology (Inst); Medtronic (Inst); Medtronic (Inst); Medtronic (Inst); Medtronic (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Sun Biopharma (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Tolero Pharmaceuticals (Inst); Vanquish Oncology (Inst); Vanquish Oncology (Inst); Vanquish Oncology (Inst); Vanquish Oncology (Inst)
 
Suzanne Gagnon
Employment - Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma
Leadership - Sun Biopharma; Sun Biopharma; Sun Biopharma; Sun Biopharma
Stock and Other Ownership Interests - Sun Biopharma; Sun Biopharma; Sun Biopharma; Sun Biopharma
Consulting or Advisory Role - Cancer Prevention Pharmaceuticals; Cancer Prevention Pharmaceuticals; Cancer Prevention Pharmaceuticals; Cancer Prevention Pharmaceuticals; ProvePharm; ProvePharm; ProvePharm; ProvePharm
Travel, Accommodations, Expenses - Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma
 
Michael T. Cullen
Employment - Sun Biopharma; Sun Biopharma; Sun Biopharma; Sun Biopharma
Leadership - Sun Biopharma; Sun Biopharma; Sun Biopharma; Sun Biopharma
Stock and Other Ownership Interests - Sun Biopharma; Sun Biopharma; Sun Biopharma; Sun Biopharma
Travel, Accommodations, Expenses - Sun Biopharma; Sun Biopharma; Sun Biopharma; Sun Biopharma
 
Michael J. Walker
Employment - Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma
Stock and Other Ownership Interests - Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma
Consulting or Advisory Role - Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma
Research Funding - Sun BioPharma; Sun BioPharma; Sun BioPharma; Sun BioPharma